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The HIV-1 Tat protein is required for viral replication and is a potent stimulator of viral transcription. Although Tat has been
extensively studied in various reductive paradigms, to date there is little information as to how this activator mediates
transcription from natural nucleosomally packaged long terminal repeats. Here we show that CREB-binding protein (CBP)/
p300 interacts with the HIV-1 Tat protein and serves as a coactivator of Tat-dependent HIV-1 gene expression on an
integrated HIV-1 provirus. The site of acetylation of Tat was mapped to the double-lysine motif in a highly conserved region,
49RKKRRQ54, of the basic RNA-binding motif of Tat. Using HLM1 cells (HIV-11/Tat2), which contain a single copy of full-length
HIV-1 provirus with a triple termination codon at the first AUG of the Tat gene, we find that only wild type, and not K50A, K51A,
or K50A/K51A alone or in combination of ectopic CBP/p300, is able to produce full-length infectious virions, as measured by
p24 gag ELISAs. Tat binds CBP/p300 in the minimal histone acetyltransferase domain (1253–1710) and the binding is stable
up to 0.85 M salt wash conditions. Interestingly, wild-type peptide 41–54, and not other Tat peptides, changes the
conformation of the CBP/p300 such that it can acquire and bind better to basal factors such as TBP and TFIIB, indicating that
Tat may influence the transcription machinery by helping CBP/p300 to recruit new partners into the transcription machinery.
Finally, using biotinylated wild-type or acetylated peptides, we find that acetylation decreases Tat’s ability to bind the TAR
RNA element, as well as to bind basal factors such as TBP, CBP, Core-Pol II, or cyclin T. However, the acetylated Tat peptide
is able to bind to core histones on a nucleosome assembled HIV-1 proviral DNA. © 2000 Academic Press
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The HIV-1 Tat protein is required for viral replication
and is a potent stimulator of viral transcription. Tat stim-
ulates viral gene expression through an RNA element in
the viral long terminal repeat (LTR). For optimal transac-
tivation of HIV-1 gene expression, Tat requires specific
upstream transcription factors, including Sp1 (Jeang et
al., 1993), TATA-binding protein (Kashanchi et al., 1994b;
Veschambre et al., 1995; Majello et al., 1998), Tat-asso-
ciated kinase (Herrmann and Rice, 1995; Yang et al.,
1996), TFIIH (Garcia-Martinez, et al., 1997; Parada and
Roeder, 1996), Tip (Jeang et al., 1993; Henderson et al.,
1999), and RNA polymerase II (Cujec et al., 1997; Ma-
vankal et al., 1996). The ability of Tat to regulate viral
transcription is related to its ability to interact with the
basal transcription complexes responsible for the initia-
tion of transcription including cyclinT1/cdk9 complex, re-
ulting in a more efficient elongating RNA Pol II complex
O’Keeffe et al., 2000; Romano et al., 1999; Napolitano et
l., 1999; Isel and Karn, 1999; Bieniasz et al., 2000; Ra-
anathan et al., 1999; Ivanov et al., 1999; Chen et al.,1 To whom correspondence and reprint requests should be ad-
ressed. E-mail: Kashanfa@umdnj.edu.
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278999a; Wimmer et al., 1999; Garriga et al., 1998; Garber et
l., 1998; Fujinaga et al., 1998; Wei et al., 1998).
Among the factors associated with basal transcription
omplexes, CBP (CREB-binding protein) and p300 have
merged as coactivators for various DNA-binding tran-
cription factors. CBP and p300 are large proteins, 2441
nd 2414 amino acids, respectively, that have the ability
o interact simultaneously with various transcription fac-
ors such as nuclear hormone receptors, CREB, c-Jun,
-Jun, c-Myb, v-Myb, Sap-1a, c-Fos, MyoD, YY1, NF-kB,
and p53 (Goldman et al., 1997) and with other coactiva-
tors such as P/CAF (Blanco et al., 1998; Chakravarti et al.,
1999), as well as with basal components of the transcrip-
tional apparatus. Therefore, it is this wide array of func-
tions that have allowed CBP/p300 proteins to be impor-
tant transcriptional integrators (Shikama et al., 1999). In
recent years multiple mechanisms have emerged for the
function of CBP/p300. The first mechanism for CBP/p300
activation involves the acetylation of the terminal tails of
the core histones by histone acetyltransferase (HAT) and
destabilization of histone–DNA interactions, allowing
transcription factors access to the promoter region. The
second mechanism by which CBP has been suggested
to be an activator of transcription is by bridging the gap
between upstream DNA-bound transcription factors and
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279ACETYLATION OF HIV-1 Tat BY CBP/P300 INCREASES VIRAL TRANSCRIPTIONcomponents of the general transcription machinery. The
third possible mechanism is CBP/p300’s ability to directly
acetylate nonhistone proteins such as p53 (Gu and Roe-
der, 1997), the erythroid Kruppel-like factor (EKLF, Zhang
and Bieker, 1998), the nuclear hormone receptor coacti-
vators ACTR (Chen et al., 1997), and the basal transcrip-
ion factor TFIIE and TFIIF (Imhof et al., 1997; Martinez-
albas et al., 1998). In the case of p53, acetylation of the
egulatory domain led to a dramatic increase in DNA
inding in vitro, whereas the acetylation of ACTR by
BP/p300 disrupts the receptor–coactivator interaction,
hich plays a key role in hormone-induced gene activa-
ion (Chen et al., 1999b).
HIV-1 proviral DNA is integrated into host cell chromo-
somes and packaged into chromatin. The LTR acts as a
very strong promoter when analyzed as naked DNA in
vitro and is silent when integrated into the cellular host
genome in the absence of any stimuli (Verdin, 1991;
Adams et al., 1994; Van Lint et al., 1996; Marzio et al.,
1998; Benkirane et al., 1998). Recently, several reports
have shown the existence of an intracellular multiprotein
complex that contains Tat, CBP/p300, and P/CAF. It was
found that the histone acetyltransferase activity of CBP/
p300 and P/CAF is preferentially required for Tat function
(Kiernan et al., 1999). CBP/p300 was also recently re-
ported to interact with the HIV-1 Tat protein and serves
as a coactivator of Tat-dependent HIV-1 gene expression
(Hottiger et al., 1998; Ott et al., 1999). This superinduction
as been attributed to the histone acetyltransferase
HAT) activity of CBP/p300 on the integrated HIV-1 pro-
oter.
In this study, we find that Tat is acetylated by CBP/
300 and mapped to the double-lysine motif in a highly
onserved region (49RKKRRQ54) of the Tat protein. Using
LM1 (HIV-11/Tat2) cells, which contain a single copy of
ull-length HIV-1 provirus with a triple termination codon
t the first AUG of the Tat gene, we find that only wild
ype, and not K50A, K51A, or a double-mutant K50A/K51A
lone or in combination with excess CBP/p300, is able to
roduce full-length infectious virions. Furthermore,
echanistically, the wild-type Tat peptide 41–54, which
ontains the basic core domain of HIV-1 Tat, changes the
onformation of CBP/p300 such that basal factors such
s TBP and TFIIB bind better to CBP/p300, indicating that
at may influence the transcription machinery by helping
BP/p300 to acquire new partners in the transcription
achinery.
Tat binds to CBP/p300 minimal HAT domain (1253–
710) and is a stable complex up to 0.85 M salt wash
onditions. Acetylation of Tat by CBP/p300 decreases
at’s ability to bind the TAR RNA element in vitro. Finally,
sing biotinylated wild-type or acetylated Tat peptides,
e find that acetylation causes a release of Tat from
asal factors such as TBP, CBP, or cyclin T. Interestingly,he acetylated Tat peptide is able to bind with higher
ffinity to core histones on nucleosomal DNA.RESULTS
IV-1 Tat is acetylated by the HAT domain of CBP/
300
We initially asked whether a minimal HAT domain of
BP/p300 was capable of acetylating the Tat protein in
itro. To answer this question, we constructed a minimal
ST–HAT plasmid from a full-length p300 cDNA clone,
xpressed in Escherichia coli and purified using gluta-
hione–agarose beads. When using GST–HAT in a
14C]acetyl coenzyme A exchange reaction, we found that
ST–HAT was capable of efficient acetylation of core
istones H2A, H2B, H3, and H4 in vitro (Fig. 1A, lane 3).
e also observed efficient acetylation of purified Tat
rotein in vitro, as shown in Fig. 1A, lane 4. Products
shown in Fig. 1A are 14C-acetylated polypeptides that
ad been separated on 4–20% SDS–PAGE, dried, and
xposed to a PhosphorImager cassette. The bottom
anel of Fig. 1A shows the Coomassie blue staining of
he same gel. It is important to note that we have con-
istently observed a more efficient acetylation of Tat
roteins that do not contain a GST moiety at their N-
erminus. Similar efficient in vitro acetylations were also
bserved with histidine- and epitope (influenza)-tagged
eptides at the N- or C-terminus of the Tat protein (data
ot shown).
We next examined the effect of various Tat peptides as
ubstrates in the in vitro HAT assay. The results of such
n experiment are shown in Fig. 1C, where Tat 41–54
eptide, but not 41–50 peptide (lanes 7–10), was acety-
ated with GST–HAT. Similar to Fig. 1A, results shown in
ig. 1C are products separated on 4–20% SDS–PAGE,
ried, and exposed to a cassette. It is important to note
hat we have observed reproducible results only when
sing [14C]acetyl CoA and SDS–PAGE (4–20%) for sepa-
ration purposes as opposed to [3H]acetyl CoA and filter
disks for detection of acetylated small peptides. Peptides
of such short lengths do not reproducibly bind to DE52
filter papers and cannot stand rigorous wash conditions.
A summary of all the Tat peptides used in the HAT assay
is shown in Fig. 1D. It is important to note that peptides
such as 65–86, which contains lysine residues, were not
acetylated, indicating that the in vitro acetylation by the
CBP/P300 HAT domain is not a nonspecific reaction.
Finally, we used wild-type full-length human HeLa p300
(hp300, a generous gift from R. Shiekhattar), or epitope-
tagged recombinant p300 (rp300), and observed efficient
acetylation of the Tat protein in vitro (Fig. 1E).
Site of Tat acetylation by the HAT domain
The Tat peptide 41–54 contains three lysine residues,
one at position 41 and the other two at positions 50 and
51. To determine which lysine residues in the 41–54
peptide were acetylated by GST–HAT, we initially made
acetylated 41–54 peptides with acetyl groups at posi-
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280 DENG ET AL.FIG. 1. Acetylation of HIV-1 Tat protein by CBP/p300 in vitro. (A, B) The core histones H2A, H2B, H3, and H4 (lanes 2 and 3) and Tat protein (1–86,
ane 4) were incubated with or without GST–p300 (HAT domain) and [14C]acetyl-CoA. (A) Acetylated products (lanes 3 and 4) resolved on 4–20%
SDS–PAGE, dried, and exposed to a PhosphorImager cassette. (A, bottom) Coomassie blue staining of the gel shown at top. B represents the purified
full-length Tat protein (1–86, 1 mg) used in the HAT assay, resolved on a SDS–PAGE gel, and silver stained (31). (C) Tat acetylation site located at the
basic RNA-binding domain. Synthesized Tat peptides covering various regions of the Tat protein (lane 3–11) were incubated with GST-p300 and
[14C]acetyl CoA and analyzed on 4–20% SDS–PAGE. Lane 2 serves as negative control with no substrate added to the reaction, and lanes 3, 4, and
1 serve as positive controls, where full-length Tat and core histone proteins were added to the reaction. All other reactions were performed with two
oncentrations (200 and 400 ng) of various peptides. (D) The schematic representation of Tat protein and Tat peptides used in this study and the
esults of acetylation by GST–p300. (E) Acetylation of HIV-1 TAT by wild-type p300/CBP. (Left) Acetylation of TAT or all four histones with 10 ng of HeLa
urified CBP/p300 complexes (hp300). Proteins, BSA, wild-type TAT, or histones were incubated with HeLa CBP/p300, followed by incubation at 37°C
or 1 h, spotted on DE52 filter discs, washed, and counted. (Right) A similar experiment with either TAT or free histones incubated with 10 ng of purified
pitope-tagged recombinant Baculovirus p300 (rp300). Samples were incubated at 37°C for 1 h and subsequently run on 4–20% SDS–PAGE, dried,
nd exposed to a PhosphorImager cassette.
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281ACETYLATION OF HIV-1 Tat BY CBP/P300 INCREASES VIRAL TRANSCRIPTIONtions 50, 51, or 50151. The acetyl groups were put on the
peptides during the chemical peptide synthesis. All pep-
tides were subsequently purified on C18 reverse-phase
HPLC and dried, and quantitations were determined by
protein assay as well as by running small aliquots on
4–20% SDS–PAGE followed by silver stain detection. As
can be seen in Fig. 2A, all peptides were efficiently
acetylated with GST–HAT, except the double-acetylated
41–54 (lanes 9 and 10). The doubly acetylated 41–54
peptide was, however, very weakly acetylated at lysine
41 position, at a 10-fold excess of GST–HAT concentra-
tions in vitro, and similar results were also obtained with
longer peptide, 36–58 (data not shown). Therefore, it
FIG. 1ay be possible that all three lysines are acetylated,
lthough at very different kinetic rates, depending on theenzyme concentrations used in these assays. To deter-
mine which lysine, 50 or 51, was acetylated efficiently in
vitro, we synthesized a second batch of acetylated pep-
tides starting from position 42–54. The results of such an
experiment are shown in Fig. 2B, where peptide 42–54,
which had already been acetylated at position 50, was a
poor substrate for accepting the new acetyl group at
position 51 (lanes 3 and 4). However, the peptide that
was acetylated at position 51 could serve as an excellent
substrate for acetylation in vitro. The doubly acetylated
42–54 peptide could not be acetylated at any concentra-
tion of GST–HAT (data not shown). We next examined the
effect of Tat acetylation on cells expressing Tat. HeLa/
inuedeTat and HeLa/pcep4 lines contain either an epitope-
tagged Tat at the C-terminus (HeLa/eTat) or a control
c282 DENG ET AL.FIG. 2. Tat acetylation sites mapped to double-lysine motifs K50 and K51 in the basic RNA-binding domain. (A, B) Two concentrations (200
and 400 ng) of the Tat peptides (41–54 or 42–54), wild-type or acetylated at lysines position 50, 51, and 50151, were incubated with GST–p300
and [14C]acetyl CoA, separated on 4–20% SDS–PAGE, and exposed to a PhosphorImager cassette. (C) Both log-phase HeLa/eTat or HeLa/pcep4
ells were labeled with [3H]acetate in DMEM complete medium plus hygromycin (left) or incubated overnight with [35S]methionine/cysteine
(right). Nuclear lysates were used for immunoprecipitations on cross-linked monoclonal 12CA5 Ab beads and eluted with a 100-fold excess of
influenza peptide. The [35S]methionine/cysteine gel was exposed overnight and the [3H]acetate gel was exposed for 1 week on the
PhosphorImager cassette.
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283ACETYLATION OF HIV-1 Tat BY CBP/P300 INCREASES VIRAL TRANSCRIPTIONbackbone vector (HeLa/pcep4). Both cell types have
been described previously (Kashanchi et al., 2000). Log-
hase-growing cells were labeled with [3H]acetate or
35S]methionine/cysteine, and nuclear extracts were ob-
ained for immunoprecipitations on cross-linked 12CA5
ntibody beads. Following binding, Tat was eluted with
n excess of competitor peptide and run on a 4–20% gel.
he results of such an experiment are shown in Fig. 2C,
here acetylated Tat (right column) could be obtained
nly from HeLa/eTat cells and not from the control pcep4
ells.
ffect of Tat acetylation on TAR and CBP/P300
inding
We next asked whether acetylation of Tat could in-
FIG. 3. Acetylated Tat decreases its ability to HIV-1 TAR RNA. (A) Th
41–54 (lanes 4–7) were incubated with 32P-labeled TAR RNA at room te
gel (Novex). Lane 1 contains TAR RNA alone and lanes 2–7 indicate TA
lanes 2 and 3, 0.5 and 1.0 mg, respectively) or GST–HAT in vitro ace
incubated with TAR RNA, resolved an a 6% DNA retardation gel, dri
increases the binding of CBP to TBP, TFIIB, and Tat. Tat peptides, wild
BP (Promega TNT, 10 ml) for 10 min and subsequently used to bind to 5
from 164 to 337 of human TBP). After several washes (33), the boundrease or decrease its affinity for TAR RNA. To address
his question, we synthesized labeled TAR RNA, PAGE
e
murified it, and used it in an RNA bandshift assay. The
esults of such an experiment are shown in Fig. 3A,
here wild-type peptide 41–54 was capable of binding to
AR RNA (lane 3). The TAR RNA binding is completely
bolished when lysines 50 and 51 are acetylated (lanes
and 7). We observed no binding of double-acetylated
0 and 51 peptide to TAR RNA at any peptide concen-
ration (data not shown). Similar results were also ob-
erved when Tat protein was acetylated with GST–HAT
rior to TAR RNA binding (Fig. 3B, lanes 4 and 5).
We next examined the effect of wild-type or acetylated
eptides on CBP/p300 binding in vitro. We reasoned that
f only wild-type Tat peptide or protein was able to bind to
AR RNA and not the acetylated counterparts, it would
hen be possible for acetylated Tat to also bind less
type Tat peptide 41–54 (lanes 2 and 3) and the acetylated Tat peptide
ture for 30 min and separated on a 6% DNA retardation polyacrylmide
various wild-type or acetylated peptides (2.5 and 5 mg). (B) Wild-type
Tat proteins (1–86, lanes 4 and 5, 0.5 and 1.0 mg, respectively) were
exposed to a PhosphorImager cassette. (C, D) Tat peptide (41–54)
various modified versions (10 mg), were preincubated with 35S-labeled
luted GST–Tat, GST–TFIIB, GST–TBP (wt), or GST–TBP (1–163, deletion
s were resolved by 4–20% SDS–PAGE, dried, and exposed.e wild-
mpera
R plus
tylated
ed, and
type orfficiently to CBP/p300. The results of such an experi-
ent are shown in Fig. 3C, where GST–Tat, but not GST,
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284 DENG ET AL.was able to bind to 35S-labeled CBP in vitro. However,
hen performing competition experiments with wild-
ype, acetylated, or alanine-substituted Tat peptides in
he same reaction, we found a surprising result, where
ild-type 41–54 but not other derivatives was able to
nhance the binding of CBP to GST–Tat (compare lanes
–5). We have found similar results when using immu-
oaffinity-purified recombinant p300 from Baculovirus-
nfected cells (data not shown). This unexpected result
uggested to us that perhaps the wild-type peptide might
hange the conformation of CBP/p300 such that it can
ind better to other proteins. This interpretation is very
ikely, since Tat has been shown to dimerize and contact
ultiple transcription factors on the transcription initia-
ion site. To test that hypothesis, we performed a similar
xperiment with CBP pretreated with either wild-type or
ouble-acetylated peptide prior to binding to other basal
actors such as TFIIB and TBP. Both TFIIB and TBP have
reviously been shown to bind to CBP/p300 molecules
Sang et al., 1997). The results in Fig. 3D indicate that
when CBP is pretreated with only wild-type Tat peptide,
it can bind more efficiently to GST–TFIIB or GST–TBP, but
not to a GST–TBP (1–163) mutant. The reaction was
specific for a possible change of CBP conformation,
since pretreatment of GST–TFIIB, TBP, or the mutant TBP
with any of the peptides did not increase CBP binding in
vitro (data not shown). Taken together, the results from
TAR binding as well as CBP binding indicate that wild-
type and not acetylated Tat binds to the basal transcrip-
tion machinery and that acetylated Tat might either com-
pletely come off the transcriptional complex or simply
stay with the elongating RNA Pol II.
Localization of CBP/p300 binding to Tat
It has previously been shown that p300 binds to Tat at
core and basic residues (Marzio et al., 1998; Benkirane et
al., 1998; Hottiger and Nabel, 1998) and that Tat binds to
the HAT, N-terminal, or C-terminal domains of p300. We
decided to determine which region of p300 was stably
binding to the Tat protein. Initially, we used a series of
four GST–CBP mutants (a generous gift from R. Good-
man) and three GST–p300 mutants in an in vitro TNT-
binding assay. Figure 4A is a general diagram that de-
picts the relationship between CBP and p300 molecules
as well as various mutants used in our assays. When
binding 35S-labeled Tat to various GST–p300 domains,
we found that Tat bound stably to all A, B, and C mutant
domains under 0.1 M salt wash conditions (Fig. 4B, lanes
1–4). However, the binding of Tat to p300 was most
resistant with the B fragment (aa 744–1540) of GST–p300.
Tat retained its binding to this fragment under 0.85 M salt
wash conditions (compare lanes 12–14). Similar results
were obtained with the GST–CBP HAT domain (data not
shown). Therefore, Tat may interact with multiple CBP/
p300 domains; however, its ability to tightly associate
p
Hwith the HAT domain may indicate similarity in functions
with other viral HAT-binding proteins such as adenovirus
E1A or SV40 large T antigen.
Functional activity of mutant Tat proteins on transient
transfections
Tat is one of the most powerful viral activators known
to date. Tat could stimulate transcription of HIV-1 pro-
moter anywhere from 100- to 1000-fold depending on the
assay conditions used. To determine which Tat residues
(position 50, 51, or 50151) were important for HIV-1
promoter activity, we synthesized alanine-substituted
vectors and sequenced all three forms of CMV-driven Tat
vectors. We subsequently used the Tat mutants in tran-
sient transfection assays using CEM (12D7) T-cells. The
results of such an experiment are shown in Fig. 5A,
where upon electroporation of K50A or K51A with re-
porter HIV-LTR CAT, we observed a slight drop in tran-
scriptional activity (less than 50%, compare lanes 3–6).
However, a more pronounced drop in transactivation
was observed with the double-mutant 50 and 51 (;5-
fold, lanes 7 and 8). This drop in activation from the
50151 mutant could not be rescued with ectopic expres-
sion of CBP vector (Fig. 5B, lane 4). Similar results were
obtained with a CMV–p300 expression vector (data not
shown). Finally to conserve the positive charge of the
lysine residues, we synthesized Tat protein with argi-
nines at positions 50 and 51 and used the protein to
perform CAT assays in CEM cells. The results in Fig. 5C
indicate that only lysine residues and not alanine or
arginine substitutions at positions 50 and 51 are critical
for the observed acetylation effect. Taken together, the
transient transfection results indicate that neither K50
nor K51 mutations alone are sufficient to completely lose
the Tat transactivation on HIV-1 LTR.
Activation of integrated HIV-1 provirus requires the
HAT domain of CBP/P300
We used HLM-1 cells to address whether the interac-
tion of Tat and CBP/p300 plays a role in the activation of
integrated proviral HIV-1 sequence in vivo. HLM-1 cells
(AIDS Research and Reference Reagent Program) were
derived from HeLa-T41 cells containing an integrated
copy of the HIV-1 proviral genome with the Tat-defective
mutation (termination linker at the first AUG). HLM-1 cells
are negative for virus particle production, but can be
induced to express high levels of infectious HIV-1 after
transfection with Tat-expressing clones or after stimula-
tion with cytokines such as TNF-a or general inducers
uch as sodium butyrate. The new resulting particles are
ild type for infection, RT activity, and integration, but
eed to be restimulated for the next round of progeny
ormation. In order to test whether coactivator CBP/p300
lays an important role in the activation of integrated
IV-1, we transfected the HLM-1 cells with Tat and CBP
b and 0.1
T r.
285ACETYLATION OF HIV-1 Tat BY CBP/P300 INCREASES VIRAL TRANSCRIPTIONand with or without E1A, which has been shown to inhibit
the HAT activity of CBP/p300 (Chakravarti et al., 1999).
FIG. 4. Binding of Tat to CBP and p300 under various salt condition
GST–p300 clones containing various domains used here, including GS
Binding of Tat to p300 under various salt wash conditions. The GST–p3
bacterial extracts and incubated with radiolabeled, in vitro translated 3
eing washed with buffers containing TNE 1 0.1, 0.3, 0.5, or 0.85 M salt
at binds only to GST–p300 B fragment after a 0.85 M salt wash buffeThe resulting supernatants were collected at various
time points and tested for the production of HIV-1 parti-cles by p24 gag antigen ELISA. The results of such an
experiment are shown in Fig. 6A, where ectopic expres-
chematic representation of functional domains in CBP, p300, and the
A (1–595), GST–p300 B (744–1540), and GST–p300 C (1540–2368). (B)
tion clones (A, B, and C) were immobilized on glutathione beads from
led Tat. The bound proteins were resolved on 4–20% SDS–PAGE after
% NP-40. Tat binds to GST–p300 B and C fragments at 0.3 M salt buffer.s. (A) S
T–p300
00 dele
5S-labesion of CBP along with Tat activates the viral production
by four- to fivefold. Furthermore, the effect of CBP acti-
286 DENG ET AL.
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287ACETYLATION OF HIV-1 Tat BY CBP/P300 INCREASES VIRAL TRANSCRIPTIONvation can be reversed using the E1A expression vector.
Interestingly, neither E1A nor CBP by itself can activate
HIV-1 production, indicating at least in the case of CBP,
that CBP exerts its activation effect on the HIV-1 pro-
moter only in the context of chromatin DNA. Therefore,
unlike other retroviral activation pathways, such as
HTLV-1 (Kashanchi et al., 1998), the HAT domain of CBP/
300 may be a crucial domain in HIV-1 proviral transcrip-
ional activation.
We next examined the effect of the Tat mutants at
ositions 50 and 51 and a combination 50151 mutant in
LM1 cells. Results presented in Fig. 6B indicate that
oint mutations at position 50 or 51 are equally delete-
ious in activation of the integrated chromatinized HIV-1
NA. This is in marked contrast to the transfection data
Fig. 5A) where point mutants at 50 or 51 were slightly
ffected and only the double-mutant 50151 vector was
ramatically reduced in activity. More importantly, ec-
opic expression of the CBP could not activate the 50 or
1 mutants in these cells. Similar levels of nuclear Tat
ild type and mutants were observed in these cells (data
ot shown). Finally, we performed a titration assay of the
at 50151 mutant with CBP and found no induction of the
atent virus in these cells (Fig. 6C). Similar results were
lso obtained with the Tat point mutants 50 or 51 and
itration of various concentrations of ectopically ex-
ressed CBP (data not shown). Taken together these
ata indicate that the effect of CBP/p300 is at the level of
ntegrated HIV-1 provirus and that both lysines at posi-
ion 50 and 51 are equally important for this activation
athway.
inding target of Tat acetylated peptide
To date there are no clear examples of what exactly
appens to a protein once it is acetylated in the tran-
criptional complex by coactivators such as CBP/p300.
n fact, the majority of the existing reports on acetylated
roteins discuss what the functional consequence of
cetylation may be (Gu and Roeder, 1997) and not so
uch regarding the proteins or pathways downstream of
cetylation. We decided to address this question by
tilizing affinity pull-down experiments using wild-type or
cetylated 42–54 peptides coupled to a biotin moiety.
he biotinylated peptides were incubated with various
FIG. 5. Mutation of the lysine residues at position 50 and 51 of Tat a
from lysates of transfected CEM (12D7) cells with LTR-CAT (3 mg) an
epresent basal transcription of LTR-CAT and Tat (1 mg) activated transc
Tat constructs into CEM cells. The mutants were pcTat (K50A, lanes 3, a
were transfected by the electroporation method and processed for CAT
of each lane. (B) Cotransfection of pcTat (K50A/K51A) alone or with CB
serve as negative controls. Titration of either pcTat (K50A/K51A) or C
at mutant construct (data not shown). (C) Transfection of various prote
hase of growth and transfected with purified synthesized TAT 72 prototal of 3 mg of LTR-CAT DNA along with 0.5 mg of TAT proteins was electro
transfection for the presence of CAT enzyme.35S-labeled proteins or nuclear extracts followed by di-
ect radioactive detection or Western blot for transcrip-
ion factors involved in HIV-1 transcription. The results of
uch an experiment are shown in Fig. 7A, where 35S-
abeled TBP, CBP, and cyclin T could efficiently bind to
ild-type but not acetylated 42–50 peptide. A similar
xperiment was performed using a purified HeLa core-
ol II fraction (Inostroza et al., 1994; Piras et al., 1994),
ollowed by Western blot for Pol II. Results from Western
lots indicated that wild-type and not acetylated peptide
as capable of binding to core-Pol II. In an attempt to
ind substrates that could bind to acetylated peptide, we
erformed a series of binding assays followed by
xcision of bound peptides from gels and subjected
hem to mass spectrometry. The initial material for
ull-down assays was whole HIV-1 virus (pDH125, a
enerous gift from M. Chow and M. Martin) reconsti-
uted in vitro with all four histones. The bound com-
lexes were washed with 150 mM salt and 0.5% NP-40,
un on SDS–PAGE, and silver-stained, and peptides
ere excised and subjected to mass spectrometry.
he results of such an experiment are shown in Fig.
B, where acetylated Tat peptide was able to bind to
ore histones. It is interesting to note that core his-
ones in the absence of DNA did not bind to acetylated
at, indicating that a fixed conformation of nucleosome
s required for Tat to bind to core histones. Therefore,
hese data collectively suggest that acetylated Tat may
eave the initiation complex behind and retain its bind-
ng to nucleosomal DNA.
DISCUSSION
In recent years it has become apparent that non-DNA-
inding transcriptional coactivators, such as p300 and
BP, that were previously thought to function primarily as
bridging” proteins between DNA-bound transcription
actors and the basal transcription complex play a critical
egulatory role as integrators of diverse signaling path-
ays in the selective induction of gene expression. Many
xamples of such phenomena are exemplified by CBP/
300’s interaction with an array of transcription factors
ncluding sequence-specific DNA-binding proteins, such
s the NF-kB CREB, or activator protein 1 (AP-1) family
embers, that interact with the promoter and act as
r reduced LTR transactivation activity. (A) CAT assays were performed
ing concentrations of CMV-Tat mutants (1 and 5 mg). Lanes 1 and 2
, respectively. Lanes 3–8 show transfection of single- or double-mutant
cTat (K51A, lanes 5 and 6), and pcTat (K50A/K51A, lanes 7 and 8). Cells
24 h later. The percentage of CAT conversion is indicated at the bottom
g) in CEM cells is shown in lanes 4 and 5, respectively. Lanes 1 and
smids showed similar results, where CBP was not able to rescue the
g with LTR-CAT reporter into CEM cells. CEM cells were grown to log
wild type, K 50/51 substituted with R, or K 50/51 substituted with A. And thei
d vary
ription
nd 4), p
assay
P (2.5 m
BP pla
ins alon
eins ofporated into CEM cells (at 230 V). Extracts were analyzed 24 h after
sfected
7 were p
288 DENG ET AL.either enhancers or repressors of gene expression dur-
ing cellular activation. Members of the p300 and CBP
family also appear to be present only in higher eu-
karoytic cells including Caenorhabditis elegans and Dro-
sophila, and not in the yeast Saccharomyces cerevisiae.
Thus, p300/CBP-like proteins are likely confined to mul-
FIG. 6. Both lysines K50 and K51 of Tat play an important role in acti
line that contains a wild-type integrated copy of the HIV-1 proviral geno
for virus particle production unless they are provided with cytokine sig
of p24 gag antigen in the supernatant. (A) Coactivation of integrated H
ng), CMV-CBP (6 mg), E1A (6 mg), or in combination with each other by
from supernatants obtained at days 3, 7, and 10 after transfection. It is in
of HIV-1 particles in HLM1 cells and E1A was able to reverse the CBP e
cells were transfected either alone with wild-type Tat and mutant Tat c
CBP into HLM1 cells and p24 gag antigen measured at various time p
HLM1 cells. Varying concentrations of the Tat double-mutant were tran
and 10 for the p24 gag ELISA assay. All experiments in A, B, and Cticellular organisms where they may fulfill specific func-
tions required for proper growth and development.
A
cMany viruses have evolved mechanisms to control
both viral and host transcriptional machinery through
CBP/p300. Generic virus infection of cells results in a
dramatic hyperacetylation of histones H3 and H4 by
CBP/p300, which is localized to target cellular promoters
such as IFN-b promoter (Parekh and Maniatis, 1999).
of the proviral integrated HIV-1 DNA. HLM1 cell is a HeLa-derived cell
ept for the Tat open reading frame. Therefore, HLM1 cells are negative
ch as TNF, or ectopic addition of Tat, as determined by the presence
virus by Tat and CBP. HLM1 cells were transfected alone with Tat (50
PO4 precipitation method. The p24 gag antigen ELISA was performed
ng to note that cotransfection of Tat plus CBP increased the production
resumably by binding to CBP and inhibiting the HAT activity. (B) HLM1
single-mutants K50A and K51A and double-mutant K50A/K51A) or with
(C) Titration of double-mutant Tat (K50A/K51A) with CBP performed in
either alone or with 6 mg of CBP. Supernatants were collected at days
erformed twice.vation
me exc
nals, su
IV-1 pro
the Ca
teresti
ffect, p
lones (
oints.lso, both DNA and RNA viruses have evolved means to
ontrol CBP/p300 in both activation and repression. For
c
c
t
n diges
try ana
289ACETYLATION OF HIV-1 Tat BY CBP/P300 INCREASES VIRAL TRANSCRIPTIONinstance, the oncogenic human papillomavirus type 16
(HPV-16) E6 binds to three regions (C/H1, C/H3, and the
C-terminus) of both CBP and p300. Interestingly, HPV-16
E6 inhibits the intrinsic transcriptional activity of CBP/
p300 and decreases the ability of p300 to activate p53-
FIG. 7. Binding of acetylated Tat to various transcription factors. (A
Western blots of the pull-down components with anti-TBP, CBP, cyclin
lysines at positions 50 and 51 were labeled with biotin at the N-term
ysteine-labeled TBP, CBP, cyclin T, and purified core-HeLa Pol II. S
omplexes. The pull-down complexes were washed three times and se
o PVDF membranes and blotted with the antibodies against TBP, CBP, c
T were also performed to confirm the Western blot data. (B) Pull-d
unacetylated Tat peptide (42–54, lane 2) or double-acetylated Tat peptide
stained with Coomassie blue, excised, subjected to digestion for trypsi
H2B, H3, and H4 were also performed to confirm the mass spectromeand NF-kB-responsive promoter elements (Patel et al.,
1999). Similarly, human herpesvirus 8/Kaposi sarcoma-associated virus IRF 1 protein also targets the carboxy-
terminal region (aa 1623 to 2414) of the transcriptional
coactivator p300 (Burysek et al., 1999). RNA retroviruses
such as MMTV, HTLV-I, and HIV have also been noted for
regulating p300/CBP. CBP suppresses the responsive-
matic representation of the pull-down experiment and the results of
ol II. The synthesized Tat peptides (42–54) with or without acetylated
he peptides were incubated with in vitro translated, [35S]methionine/
idin–agarose beads were used to pull down the peptide-associated
on the 4–20% SDS–PAGE gel. For Western blots they were transferred
and Pol II. Pull-down experiments with 35S-labeled TBP, CBP, and cyclin
mplexes from chromatin assembled HIV-1 DNA with the wild-type
4) at positions 50 and 51 lysines (lane 3) were separated on SDS–PAGE,
t, and analyzed by mass spectrometry. Western blots for histones H2A,
lysis (data not shown).) Sche
T, and P
inus. T
treptav
parated
yclin T,
own co
(42–5ness of the mouse mammary tumor virus (MMTV) pro-
moter to dexamethasone in a dose-dependent fashion
r
(
H
t
(B) The
290 DENG ET AL.(Kino et al., 1999), as well as alleviating NFI-C-mediated
epression of MMTV by ectopic expression of p300/CBP
Chaudhry et al., 1999). Transcriptional activation of the
TLV-I sequences by Tax and CBP is induced by reini-
iation of transcription (Kashanchi et al., 1998), and cyto-
kine and Tat regulation of HIV transcription requires
binding of the p300 coactivator to the promoter region
(Hottiger et al., 1998; Hottiger and Nabel, 1998; Benkirane
et al., 1998; Marzio et al., 1998; Kiernan et al., 1999; Ott et
al., 1999).
CBP/p300 acetylates the core histones as well as
nonhistone proteins such as the tumor suppressor pro-
tein p53, the hematopoietic transcription factor GATA-1,
and the basal transcription factors TFIIE and TFIIF, al-
though their biological functions are still not well under-
stood. To test whether HIV-1 Tat could also be specifi-
cally acetylated by CBP/p300, we used the purified full-
length Tat (1–86) protein and found that the labeling was
completely dependent on the presence of the CBP/p300
HAT domain. The labeling was most efficient with puri-
fied Tat and not GST–Tat (1–101), GST–Tat (1–86), GST–
Tat (1–72), or 17 other GST–Tat mutants.
FIG. 8. A general scheme of various Tat domains. (A) Conservation
and peptides used in this study were of North American Clade B type.
which are also acetylated by CBP/p300 as indicated by asterisks.When using Tat peptides to pinpoint the amino acid
residues important for acetylation, we found that the bothlysines in the highly conserved region (49RKKRRQ54) of
the basic RNA-binding motif of Tat were acetylated by
CBP/p300 (see Fig. 8). Importantly, upon transfection of
K50A or K51A Tat vectors with reporter HIV-LTR CAT, we
observed a slight drop in transcriptional activity but a
more pronounced drop in transactivation with the dou-
ble-mutant K50A and K51A. This suggested that both
lysines together are important in the transient transfec-
tion assays. However, when using HLM1 cells, contain-
ing integrated virus, we observed that both point muta-
tions at position 50 and 51 were equally deleterious in
activation of the integrated chromatinized HIV-1 DNA and
that ectopic expression of the CBP could not activate
either of the 50 or 51 mutants in these cells. Therefore,
we believe that both lysines are equally important for in
vivo activation of the latent virus.
When examining for the effect of wild-type or acety-
lated Tat on RNA binding, we found that the acetylated
Tat peptide or protein was not able to bind to TAR RNA.
This is in marked contrast to other acetylated proteins
such as p53, where acetylation increases the DNA-bind-
ing activity (Gu and Roeder, 1997). More interestingly,
ouble-lysine motif of Tat among various HIV-1 clades. The Tat protein
double-lysine motifs of Tat resemble those in p53 and ACTR proteins,of the dwhen performing competition experiments with wild-
type, acetylated, or alanine-substituted Tat peptides in
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291ACETYLATION OF HIV-1 Tat BY CBP/P300 INCREASES VIRAL TRANSCRIPTIONthe same reaction, we observed that wild-type 41–54 but
not other derivatives was able to enhance the binding of
CBP to Tat as well as other basal factors such as TFIIB
and TBP. This intriguing result indicates that CBP/p300
family members are subject to conformational change
upon binding to viral and possibly cellular activators. In
support of the change of conformation hypothesis, we
have recently obtained preliminary data suggesting that
in vitro translated CBP in presence of wild-type but not
acetylated Tat peptide is susceptible to endoproteinase
Glu-C digestion and not to other nucleases such as
trypsin, endonuclease Asp-N, or Lys-C proteases.
CBP/p300’s ability to acetylate Tat has recently been
examined in a chromatin reconstitution experiment.
When using purified basal transcription factors NF-kB,
P1, and cdk9/cyclin T in an in vitro transcription reac-
ion, where the HIV-1 DNA is chromatinized, we ob-
erved no activated transcription in vitro, indicating that
he mere presence of cdk9/cyclinT is not sufficient to
rive RNA pol II through chromatin DNA. However, only
n the presence of added minimal p300 HAT domain or
ild-type p300 do we find activated transcription on
IV-1 DNA (Deng, unpublished data). Therefore, the role
f the cdk9/cyclinT complex in HIV-1 transcription may
e to phosphorylate the CTD of RNA pol II and that of
300 may be to acetylate the natural core histones on the
IV-1 genome. To this end, we have mapped the pro-
oter region (2500 to 1200) of 26 different HIV-1 clade
solates ranging from subtypes B to O and have ob-
erved that all viral isolates have chromatinized DNA in
ivo, further indicating that the HIV-1 B clade that we
ave used in this study (in HLM1 cells) was not the only
IV-1 chromatinized template in vivo. Finally, our results
how that the acetylated Tat decreases Tat’s ability to
ind the TAR RNA element, as well as to bind basal
actors TBP and core-Pol II, but increases the efficiency
f binding to core histones and only when assembled as
nucleosomal HIV-1 DNA. This notion may provide a
echanism of how Tat is able to leave the initiation
omplex behind and to facilitate chromatin modification
r remodeling downstream of the transcription initiation
ite, perhaps by aiding in disruption of the nuc-1 nucleo-
ome. El Kharroubi et al. (1998) demonstrated that ex-
ression of a functional Tat could alter the chromatin
tructure downstream of the HIV-1 promoter and that the
inding of Tat to TAR (as occurs with Tat K41T) failed to
nduce chromatin remodeling. Recently, using in vitro
econstituted chromatin templates, we found that Tat–
300 interaction increases the acetylation of a nucleo-
omal histone. Such enhancement of histone acetylation
ay be due to the finding that the acetylated Tat binds
ith higher efficiency to nucleosomal DNA and changes
he conformation, resulting in the accessibility of histone
ails to p300. Acetylation of histones may flag other
roteins needed for disruption of nuc-1 and subsequent
ranscription. Future experiments will determine the nu-
1
hleosomal position(s) that is affected by acetylated Tat
n whole HIV-1 DNA.
MATERIALS AND METHODS
ell culture and labeling
Log-phase CEM (12D7) T-lymphocytes (Kashanchi et
l., 1992, 1994a, 1994b) were grown in culture at 37°C up
o 1 3 105 cells/ml in RPMI 1640 medium containing 10%
etal bovine serum treated with a mixture of 1% strepto-
ycin, penicillin, and 1% L-Glutamine (Gibco BRL).
HLM-1 cells (AIDS Research and Reference Reagent
Program, Catalog No. 2029) were derived from HeLa-T41
cells integrated with one copy of the HIV-1 genome
containing a Tat-defective mutation. The mutation was
introduced as a triple termination linker at the first AUG
of the Tat gene (Sadaie and Hager, 1994). HLM-1 cells
are negative for virus particle production, but can be
induced to express noninfectious HIV-1 particles after
transfection with Tat cDNA or mitogens such as TNF-a or
sodium butyrate. HLM1 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 100 mg/ml
f G418, plus 1% streptomycin, penicillin, and 1% L-glu-
tamine (Gibco BRL). These cells were always grown to
75% confluency before transfection or passages.
Labeling experiments were performed on log-phase
75% confluent HeLa/eTat or control HeLa/pcep4 cells
(Kashanchi et al., 2000). Cells were pulsed for 3 h with
[3H]acetate (0.4 mCi, ICN) in complete DMEM plus hy-
romycin. Cells were also incubated overnight with
35S]methionine/cysteine (0.2 mCi/ml, NEN) in methio-
nine/cysteine-free medium and 10% dialyzed FCS. Nu-
clear lysates were prepared in 1 ml of lysis buffer (300
mM NaCl, 0.1% NP-40, 10 mM NaH2PO4, 1 mM EDTA, pH
8, 1 mM DTT, 50 mM sodium pyrophosphate, 10 mM NaF,
8 mM sodium butrate), and immunoprecipitations were
performed on 0.5 mg protein extract. Tat was detected
using immunoprecipitation from cellular lysates with
monoclonal 12CA5 Ab cross-linked to beads for 3 h and
eluted with a 100-fold excess of influenza peptide for 8 h
at 4°C. The sequence of peptide used for elution was as
follows: NYPYDVPDYASLC. Four independent [3H]acetate
and [35S]methionine/cysteine labeling experiments were
erformed with similar results.
ymphocyte transfection
Lymphocytes (CEM, 12D7) were grown to mid-log
hase of growth and were processed for electroporation
ccording to a previously published procedure (Kashan-
hi et al., 1992). Only one modification was introduced,
here cells were electroporated at 230 V and plated in0 ml of complete RPMI 1640 medium for 18 h prior to
arvest and CAT assay.
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292 DENG ET AL.Transfection and HIV-1 detection of HLM1 cells
HLM1 cells were propagated in DMEM (containing 100
mg/ml of G418) and transfected with the plasmid DNAs
including Tat, mutant Tat, and CBP using the calcium
phosphate method. The transfected cells were washed
after 4 h and fresh complete DMEM with 10% fetal bovine
was added for the remainder of the experiment. The p24
gag antigen was detected with a standard ELISA kit
(Abbott) using the supernatants of transfected cells at
days 3, 7, and 10.
Plasmids
HIV-LTR-CAT reporter and eukaryotic Tat expression
vectors (pcTat) have been described previously
(Hauber et al., 1989; Kashanchi et al., 1994b). Mutants
f the lysine residue at position 50 and/or 51 of the Tat
xpression plasmid were constructed from pcTat, by
eplacing the EcoNI fragment with synthesized mu-
ated oligo adaptor. The following top strands for each
utated construct are indicated: for K50A, 59GGCAGG-
CGAAGCGGAGACAGCGACGAAGACCTCC39; for K51A,
59GGCAGGAAGGCGCGGAGACAGCGACGAAGACCTCC39;
and for K50/A1K51/A, 59GGCAGGGCGGCGCGGAGAC-
AGCGACGAAGACCTCC39. Eukaryotic expression vectors
for CBP E1A have previously been reported (Chakravarti et
l., 1999). GST–p300 (HAT) from aa 1197 to 1735 was PCR
mplified from a p300 B fragment as well as the p300 C
ragment and subcloned into pGEX (more details of sub-
loning will be provided upon request). The resulting re-
ombinant vector was transformed into E. coli DH5a and
ere grown overnight in 10 ml of LB with 100 mg/ml of
ampicillin. A 500-ml LB 1 ampicillin flask was inoculated
with the overnight culture and was grown for 4 h at 37°C.
Isopropyl-1-thio-b-D-galactopyranoside was added to a final
oncentration of 0.1 mM to induce fusion protein expres-
ion, and the culture was switched to 30°C for an additional
h. Cells were collected by centrifugation in a GSA rotor at
800 g for 10 min at 4°C. For sonication, the bacterial pellet
as resuspended in 25 ml of phosphate-buffered saline
ontaining 1 mM phenylmethylsulfonyl fluoride and was
onicated (Branson) for 35 pulses at the 3.5 microprobe
etting. The resulting mixture was centrifuged in a GSA
otor at 5800 g for 10 min at 4°C. A second centrifugation in
SS-34 rotor at 23,500 g for 20 min at 4°C clarified the
xtract of remaining debris. GST–fusion proteins were
ound to agarose beads overnight, washed the next day,
nd run on 4–20% SDS–PAGE for both quality and quantity
rior to use in HAT assays.
aculovirus expression and protein purifications
Sf9 cells were grown to mid-log phase in HyClone HyQ
CM-3 serum-free medium utilizing spinner flask culture
ethods. For p300 infection, the cells were infected with
1 ml of p300 FLAG virus at 2.0 3 106 cells/ml and thenllowed to incubate at 10 rpm for approximately 1 h. After
his initial incubation/infection time the spinner plates
ere turned up to 70 rpm for the remainder of the
ncubation. The cells were collected via centrifugation
8 h after infection. The cell culture normally yielded
pproximately 2 ml of PCV from 500 ml of original culture
olume, and the cell pellet was processed for further
urification. Samples were lysed with lysis buffer, con-
aining 50 mM Tris–Cl, pH 7.4, 120 mM NaCl, 5 mM EDTA,
.5% NP-40, 50 mM NaF (phosphotyrosine phosphatase
nhibitor), 1 mM DTT, and 1 mM PMSF, and processed
ith 12CA5 monoclonal antibodies for further purifica-
ions.
istone acetyltransferase assay
HAT assays were performed as 30-ml total reactions at
7°C for 60 min in buffer containing 1 ml of purified
ST–p300 HAT (1 mg/ml), 200–400 ng substrate proteins
r peptides, and 1 mg of histones H2A, H2B, H3, and H4
in 20 mM HEPES–NaOH, pH 7.4, 1 mM dithiothreitol, 10
mM sodium butyric acid, and 1 ml of [14C]acetyl-Coen-
zyme A (65 mCi/mmol, ICN). Proteins and peptides were
resolved on 4–20% or 15% SDS–PAGE. Gels were dried
and exposed to a PhosphoImager cassette.
Preparation of TAR RNA and RNA-binding
experiments
The plasmid pT7 was constructed from pU3R-III con-
taining a T7 promoter at nucleotide 11 of HIV (Gunnery
et al., 1990). pT7 was linearized at nucleotide 182 by
digestion with HindIII and transcribed using T7 RNA
polymerase (Promega). TAR RNA was labeled with
[a-32P]UTP and was subjected to electrophoresis in a
0% polyacrylamide gel. The major radioactive RNA band
as eluted and extracted with phenol/chloroform and
recipitated with ethanol.
Gel mobility shift reaction (16-ml final reaction volume)
as carried out in binding buffer (10 mM HEPES, pH 7.3;
00 mM KCl; 1 mM MgCl2; 0.5 mM EDTA; 1 mM DTT; and
0% glycerol) and contained 3 ng of labeled TAR RNA as
ell as 200 ng tRNA as nonspecific competitor. Reac-
ions were incubated for 30 min at room temperature and
NA-bound complexes were separated on a prerun 6%
NA retardation gel (Novex) containing 0.53 TBE buffer,
t 7 W for 2.5 h at 4°C.
eptide synthesis
The biotinylated peptides were prepared on a PAL–
EG–polystyrene resin by continuous-flow solid-phase
ynthesis on a PerSeptive Biosystems Pioneer synthe-
izer (Framingham, MA) using HBTU-activated Fmoc
mino acids. Side chain protection was as follows: Arg
Pmc), Gln (Trt), Lys (Dde), Ser, and Tyr (But). Peptide
aassembly was concluded by N -acylation with HBTU-
activated biotin. The resin-bound peptide was then
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tively remove the Dde groups from the side chain of Lys.
The resin was then divided into two equal portions and
one-half was subjected to a 1-h treatment with an excess
of acetic anhydride in the presence of an equivalent
amount of base to acetylate the resulting free Ne groups.
oth peptides were then separately cleaved from the
olid support and simultaneously the remaining side
hain was deprotected by reaction with trifluoroacetic
cid in the presence of scavengers. Peptide purification
as achieved by conventional reverse-phase HPLC on
ydac C18 (Hesperia, CA) in an overall yield of 25–30%
ased on starting resins. The purity of the two peptides
as confirmed by analytical reverse-phase HPLC, capil-
ary zone electrophoresis, and matrix-assisted laser de-
orption time of flight mass spectrometry. For the non-
cetylated peptide, we found MH1 1757.5 (calc. MH1
1757.1). For the acetylated peptide, we found MH1 1840.9
(calc. MH1 1840.1).
Synthesis of acetylated peptides at positions 50, 51,
nd 50151 was carried out on the ABI 433A Peptide
ynthesizer (PE Biosystems, Foster City, CA) using Fast-
oc chemistry with Ne-acetyl-L-lysine, which was pur-
chased from Novabiochem (San Diego, CA). After cleav-
age and deprotection, the peptides were purified by
HPLC (Dionex, Sunnyvale, CA) using an acetonitrile gra-
dient on a C18 reverse-phase column (Pharmacia, Pis-
cataway, NJ). The amount of protein was determined by
Bio-Rad protein assay as well as by running small ali-
quots on 4–20% SDS–PAGE followed by silver staining.
Streptavidin bead pull-down assay
Synthesized Tat (42–54) peptides, labeled with biotin
at the N-terminus, and with or without an acetyl group at
lysines 50 and 51, were used in the pull-down assays.
The biotin-labeled Tat peptides were incubated with the
cell extracts in TNE50 buffer (100 mM Tris–HCl, pH 7.5; 50
M NaCl; 1 mM EDTA; 0.1% NP 40) at 4°C overnight.
treptavidin beads (Boehringer Mannheim) were added
o the mixture and incubated for 2 h at 4°C. The beads
ere washed three times with TNE150 (100 mM Tris–HCl,
pH 7.5, 150 mM NaCl; 1 mM EDTA; 0.1% NP-40). The
bound proteins were separated on 4–20% SDS–PAGE
and subjected to Western blotting with antibodies
against TBP, CBP, cyclin T, and RNA polymerase II (Santa
Cruz Inc.; SC-900 (C21) for Pol II, Sc-1211 (451) for CBP,
Sc-204 (N12) for TBP, and cyclin T (a generous gift from
M. Mathews).
Nucleosome reconstitution by salt dialysis
The core histones were purified from HeLa cells by the
method of Simon and Felsenfeld (1979). Chromatins
were prepared from high-molecular-weight DNA and
plain and purified core histones by dialysis from 1 M
NaCl (Imbalzano, 1998; Stein, 1989). Ten micrograms of Bplasmid DNA of pDH125 (whole HIV-1 genome, a gener-
ous gift from M. Cho and M. Martin, NIAID/NIH) was
mixed with 5 ml of 5 M NaCl and 2 ml of 103 reconsti-
tution buffer (0.15 M Tris–HCl, pH 7.5; 1 mM DTT; 2 mM
EDTA) by pipetting up and down repeatedly. Later, 15 mg
of core histones was added in a total volume of 20 ml; the
volume was adjusted by adding ddH2O. Samples were
gently flicked in the tube to mix and incubated at 37°C for
20 min. Sequential dilution was carried out by adding 10
ml of 13 reconstitution buffer every 10 min, for 3 h at
37°C. At each time point, samples were mixed by pipet-
ting up and down. An aliquot was run on agarose gels to
ensure proper assembly prior to each experiment.
In-gel digestion, mass spectrometry, and protein
identification
The in-gel digestion was performed based on a pro-
cedure previously described by Fernandez et al. (1998).
The gel bands of interest were excised from SDS–PAGE
and digested with 0.2 mg of trypsin (Promega modified
sequencing grade trypsin). The digests were desalted
using C18 ZipTips (Millipore) according to the manufac-
urer’s protocol. A 1-ml aliquot of sample was taken for
eptide mass mapping on a PerSeptive Biosystem
EPRO MALDI–TOF Mass Spectrometer using a-cyano-
4-hydroxycinnamic acid as the matrix. Analysis was per-
formed in the linear delayed-extraction mode, with exter-
nal calibration. Protein identification by mass mapping
was performed through the ProFound Web site located at
Rockefeller University (prowl.rockefeller.edu).
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